Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Transcode Therapeutics, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 6 | 8 | +2 |
| Shares | 3.88K | 30.9K | +27.0K (+695.5%) |
| Value | $26.4K | $265.7K | +$239.2K (+904.6%) |
New holders (4)
Institutions that held Transcode Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 12,740 | $109.7K | 0.00% |
| Vanguard Capital Management LLC | 6,545 | $56.4K | 0.00% |
| Vanguard Fiduciary Trust Co | 2,982 | $25.7K | 0.00% |
| Wells Fargo & Company | 55 | $474 | 0.00% |
Sold out (2)
Institutions that held Transcode Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Bank of America Corp | 8 | $55 |
| Advisor Group Holdings, Inc. | 3 | $20 |